The shadow of generic challenges has consistently loomed above copyright’s famous drug, Viagra, raising questions about the outlook of connected pharmaceutical holdings. While first times saw impressive profits, the intellectual property lapse has created the door for cheaper substitutes, likely diminishing revenue and creating a significant dang